Apr. 30 at 9:33 AM
$XERS "Not many" Bio companies can demonstrate potential growth of ~100% within just two years, from
$203M in 2024 to nearly
$400M in 2026.
This is especially compelling given that such growth may be achieved alongside ~87% gross margins nowadays, as the company approaches growing profitability and self-sustainability.
A key driver is Recorlev, which, in my view, could prove stronger than Korlym, as it directly lowers cortisol, pool of roughly 80% of the patient population. Korlym helped propel Corcept to a peak of about
$118!! a year ago, when Corcept's narrative was stronger, based just on ~
$700M revenue!
Even if considering 35% less shares outstanding, it's still as ~
$80 peak for Xeris.
Meanwhile, Xeris Biopharma retains a compelling story, combining Recorlev's blockbuster potential with XP-8121->A potential bonanza asset, with Phase 3 expected soon. As the only SQ levothyroxine option, it offers meaningful revenue potential of
$2-3B with ~90% specialty-drug margins
